We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance ... Iterum Therapeutics PLC is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. Show more
DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat...
-- ORLYNVAHTM Approved by FDA on October 25, 2024โ --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2449 | -12.1538461538 | 2.015 | 2.05 | 1.625 | 1135090 | 1.78255876 | CS |
4 | -0.0249 | -1.38718662953 | 1.795 | 3.02 | 1.625 | 1542312 | 2.20557524 | CS |
12 | 0.7101 | 66.9905660377 | 1.06 | 3.02 | 0.808 | 3003412 | 1.8057037 | CS |
26 | 0.6701 | 60.9181818182 | 1.1 | 3.02 | 0.808 | 1542205 | 1.74425567 | CS |
52 | 0.0801 | 4.73964497041 | 1.69 | 3.02 | 0.808 | 967083 | 1.71092542 | CS |
156 | 1.3001 | 276.617021277 | 0.47 | 3.1305 | 0.175 | 930520 | 0.87141265 | CS |
260 | -1.1199 | -38.7508650519 | 2.89 | 6.47 | 0.175 | 3604210 | 1.35832557 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions